 CytoDyn Inc said a research paper indicated that its flagship drog leronlimab shows activity against 4-Class drug-resistant HIV-1 from heavily treatment-experienced HTE subjects. The Vancouver, British Columbia-based company noted that the research paper entitled Leronlimab PRO 140 activity against 4-class drug-resistant HIV-1 from Heavily Treatment Experienced Subjects has been accepted, peer-reviewed and is available as a journal pre-proof on ScienceDirect. 